Jefferies lowers Inspire Medical Systems stock price target to $160 from $205

Published 05/08/2025, 18:14
Jefferies lowers Inspire Medical Systems stock price target to $160 from $205

Investing.com - Jefferies has reduced its price target on Inspire Medical (TASE:BLWV) Systems (NYSE:INSP) to $160.00 from $205.00 while maintaining a Buy rating on the stock. The medical device company, currently trading at $75.17, is showing strong financial fundamentals with a "GREAT" health score according to InvestingPro analysis, despite trading near its 52-week low.

The price target adjustment follows Inspire Medical’s second-quarter sales beat, which was offset by slower progress on the Inspire 5 rollout and impacts from GLP-1 medication trials.

These factors led Inspire Medical Systems to reset its fiscal year 2025 sales guidance lower to $900-$910 million, representing 12-13% year-over-year growth, down from the previous guidance of $940-$955 million, which had projected 17-19% growth.

The revised guidance falls below consensus estimates of $949 million, which had anticipated 18% growth for the medical device company.

Inspire Medical also provided third-quarter sales guidance of $219-$224 million, projecting 8-10% year-over-year growth for the period.

In other recent news, Inspire Medical Systems reported second-quarter revenue of $217.1 million, surpassing Wall Street’s forecast of $214.3 million. Despite this, the company posted a GAAP earnings per share loss of $0.12 and adjusted EPS of $0.45, beating the consensus expectations of a $0.20 loss. Several analyst firms have revised their outlooks for Inspire Medical Systems. Piper Sandler lowered its price target to $150.00, citing challenges with the Gen 5 product launch. RBC Capital also reduced its target to $180.00, highlighting a significant guidance reduction for 2025. Stifel adjusted its target to $140.00 due to lagging Inspire V facility activations. Truist Securities downgraded the stock from Buy to Hold, cutting the target to $125.00 amid growth concerns. Lastly, Mizuho (NYSE:MFG) lowered its target to $170.00 following a reduction in full-year guidance and adjusted earnings expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.